Permanent Health Funds for Higher Education (Fund 810)

Permanent Health Funds will be assigned to schools to support health education, research programs, and infrastructure operations.

Strategy F.1.2., Tobacco Permanent Health Fund

FY 2019 U.B. $1,152,272

FY 2020 Income:
- Regular Appropriations $1,714,013
- Revised Receipts - Distributions (246,175)
- Revised Receipts – Interest Income 27,000

FY 2020 Available Method of Finance $2,647,110

FY 2020 Expenditures Budget:

- Nursing School – Faculty Support and Technology Upgrades
  FTEs – 13.12

  Salaries and Wages $1,025,591
  Other Personnel 143,793
  Other Operating 245,229
  Total $1,414,613

- School of Health Professions Departmental Administration
  FTEs – 0.85

  Salaries and Wages $56,374
  Other Personnel 11,645
  Other Operating 194,273
  Total $262,292

- Institutional Research Grant Program
  FTEs – .32

  Salaries and Wages $31,644
  Other Personnel $8,595
  Other Operating 384,066
  Total $424,305
• Cancer Research Partnership Initiative
  FTE’s – 0.00

  Other Operating  184,446
  Total $184,446

• Research Studies in Biomedical Sciences
  FTE’s – 1.00

  Salaries and Wages $69,000
  Other Personnel $17,250
  Other Operating  248,500
  Total $334,750

• Summary of Permanent Health Funds Expenditures
  FTE’s – 15.29

  Salaries and Wages $1,182,609
  Other Personnel  181,283
  Capital Outlay  0
  Other Operating  1,256,514

  FY 2020 Total Expenditures Budget $2,620,406
  FY 2020 U.B. (Estimated) $26,704
Greehey Children's Cancer Research Institute

The primary mission of the Greehey Children’s Cancer Research Institute (Greehey CCRI) is to advance scientific knowledge relevant to childhood cancer, to contribute to the understanding of causes of childhood cancer, and to accelerate the translation of knowledge into novel therapies. Through discovery, development, and dissemination of new scientific knowledge, Greehey CCRI strives to have a national and global impact on the problem of childhood cancer. Research strengths include cancer genomics, RNA metabolism and sarcoma biology. We are developing expertise in drug delivery, with a focus on nano-technology and protein structure and function, which will be further developed. A focus on developmental therapeutics continues to increase.

The educational mission is to train the next generation of researchers in pediatric cancer research. This includes creating a pipeline of trainees through a program for undergraduates engaged in summer research, medical students within the MD with Distinction in Research program, fellows in the ACGME-approved hematology-oncology fellowship program, as well as the traditional graduate programs in Cancer Biology and other relevant areas. Greehey CCRI also provides a nurturing home for post-doctoral graduate research training.

Greehey CCRI interacts with members of the Division of Pediatric Hematology-Oncology to provide support for clinical research, banking of clinical specimens and annotation of such specimens to facilitate patient-oriented research. In addition, as our research mission includes performing research that translates into clinical care, the Greehey CCRI supports infrastructure for human subjects' research and investigator-initiated trials in pediatric cancer. Since much of research in pediatric cancer includes participation in cooperative group trials, Greehey CCRI supports the involvement of investigators in Children’s Oncology Group participation. The UT Health Cancer Center is a member of The Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC). POETIC’s pediatric oncology studies focus on the biologic basis for anti-cancer therapy, and in particular, attempt to explore and evaluate new agents and novel combinations of therapies early in clinical development.

The program equips, maintains, and operates the Greehey CCRI research building; recruits staff scientists and collaborators; expands programs in bioinformatics, cancer control, cancer genetics, experimental therapeutics, hematological malignancies, molecular oncogenesis, pediatric preclinical testing; and continues a lecture series. The program has recently upgraded and continues to develop its next generation gene sequencing with bioinformatics support. Greehey CCRI researchers have developed more novel therapies in national pediatric trials than any other group in the U.S. Treatments that have been developed are standard of care in the U.S., Europe and Asia for high-risk solid tumors.

The program leverages its expenditures with extramural funding from the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, and a variety of public and private entities.
Strategy F.1.1., Tobacco Earnings - UTHSCSA
FTEs – 61.55

<table>
<thead>
<tr>
<th>FY 2019 U.B.</th>
<th>$19,368,107</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>FY 2020 Income:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Appropriations</td>
<td>$12,791,167</td>
</tr>
<tr>
<td>Revised Receipts - Distributions</td>
<td>0</td>
</tr>
<tr>
<td>Revised Receipts – Interest Income</td>
<td>508,833</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FY 2020 Available Method of Finance</th>
<th>$32,668,107</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>FY 2020 Expenditures Budget:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Activities:</td>
<td></td>
</tr>
<tr>
<td>Salaries and Wages</td>
<td>$5,100,637</td>
</tr>
<tr>
<td>Other Personnel</td>
<td>1,267,663</td>
</tr>
<tr>
<td>Other Operating</td>
<td>3,262,575</td>
</tr>
<tr>
<td>Infrastructure Support:</td>
<td></td>
</tr>
<tr>
<td>Other Operating</td>
<td>$600,000</td>
</tr>
<tr>
<td>Capital Outlay</td>
<td>$449,084</td>
</tr>
<tr>
<td>Debt Service</td>
<td>$3,636,250</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FY 2020 Total Expenditures Budget</th>
<th>$14,316,209</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>FY 2020 U.B. (Estimated)</th>
<th>$18,351,898</th>
</tr>
</thead>
</table>